Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer

Kim, Sun I.l; Kwon, Soie; Kim, Young Sig; Hong, Sung Joon

doi:10.1016/s0090-4295(02)01909-x

Cited by 56 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study of a pathologically homogeneous group of patients with pT 1 and grade 3 TCC of the bladder, the expression of COX-2 was correlated with recurrence and progression. Thus, patients with COX-2-positive superficial bladder cancer may need to be followed up more vigorously (35). Collectively, these results indicate that COX-2 is widely expressed in human bladder carcinomas and COX-2 inhibition may allow chemopreventive intervention.…”

Section: Discussionmentioning

confidence: 93%

Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer

Moussa

Yordy²,

Abol‐Enein

et al. 2005

Cancer Research

View full text Add to dashboard Cite

Thromboxane synthase (TXAS) is one of the enzymes downstream from cyclooxygenase-2 and catalyzes the synthesis of thromboxane A 2 (TXA 2 ). TXAS was among the genes we identified based on its overexpression in invasive bladder tumors. TXAS is overexpressed in common forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squamous cell carcinoma, and 5 of 11 (45.5%) adenocarcinoma relative to nontumor tissue. Overall, 112 of 161 (69.5%) invasive tumors exhibited elevated expression. Significantly, patients with tumors having >4-fold levels of TXAS expression showed significant statistical evidence of lower overall survival expressed by the estimated hazard ratio of 2.74 with P = 0.009 in Cox's regression analysis. TXAS mRNA expression was found to be an independent prognostic marker for patients with bladder cancer. Treatment of bladder cancer cell lines (T24 and TCC-SUP) with TXAS inhibitors and TXA 2 (TP) receptor antagonists reduced cell growth, migration, and invasion, whereas TP agonists stimulated cell migration and invasion. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor invasion and metastases and suggests that modulation of the TXAS pathway may offer a novel therapeutic approach. (Cancer Res 2005; 65(24): 11581-7)

show abstract

Section: Discussionmentioning

confidence: 93%

Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer

Moussa

Yordy²,

Abol‐Enein

et al. 2005

Cancer Research

View full text Add to dashboard Cite

show abstract

“…The specimens were considered as COX-2 positive if at least 5% of tumor cells revealed light brown cytoplasmic immunostaining (Shirahama, 2000;Kim et al, 2002;Wadhwa et al, 2005;Jang and Lee, 2009). …”

Section: Immunohistochemistrymentioning

confidence: 99%

Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics

Tabriz

Olfati²,

Ahmadi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…According to Shirahama et al (27), COX-2 expression is not a prognostic factor. However, Kim et al (28) reported that COX-2 expression could predict recurrence and progression of T1, grade 3 bladder carcinoma. Further evaluation with a greater number of cases would appear to be needed.…”

Section: P=003 -------------------------------------------------mentioning

confidence: 99%

Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder

et al. 2008

View full text Add to dashboard Cite

Abstract. Cyclooxygenase-2 (COX-2) activity is reported to increase apoptosis, inhibit angiogenesis and reduce metastasis. We analyzed COX-2 expression in patients with invasive bladder cancer to evaluate the feasibility of selective COX-2 inhibitor treatment targeting COX-2. Forty patients with pathologically diagnosed invasive transitional cell carcinoma of the urinary bladder (pT2-pT4) were evaluated. Immunohistochemical staining was used to evaluate COX-2 expression, and cases with staining of ≥10% of tumor cells were defined as positive. In 2 patients, 0% of the primary tumors stained for COX-2, while 1-5% was stained in 16 patients, 5-10% in 3 patients and ≥10% in 19 patients (19/40, 47.5%). In terms of grade, 2 patients with grade 2 (2/3, 66.6%) and 17 patients with grade 3 (17/37, 45.4%) were COX-2 positive. When categorized by stage, 11 patients with pT2 (11/22, 50.0%), 6 with pT3 (6/13, 46.1%) and 2 with pT4 (2/5, 40.0%) were positive. Lymph node metastasis was observed in 10 patients; 2 of them, with pN2, were COX-2 positive. Those with COX-2-positive metastatic lymph nodes had grade 3 primary tumors, which were also COX-2 positive. In addition, COX-2-negative metastatic lymph node patients also had negative primary tumors. The results of this study suggest that 47.5% of patients with invasive bladder cancer may benefit from treatment with selective COX-2 inhibitors targeting COX-2, and that treatment efficacy can be expected in patients with lymph node metastasis when their primary tumors are COX-2 positive.

show abstract

Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer

Cited by 56 publications

References 21 publications

Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer

Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer

Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics

Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder

Contact Info

Product

Resources

About